PL2209375T3 - Związki, kompozycje i metody stosowania inhibitorów PARP - Google Patents
Związki, kompozycje i metody stosowania inhibitorów PARPInfo
- Publication number
- PL2209375T3 PL2209375T3 PL08836018T PL08836018T PL2209375T3 PL 2209375 T3 PL2209375 T3 PL 2209375T3 PL 08836018 T PL08836018 T PL 08836018T PL 08836018 T PL08836018 T PL 08836018T PL 2209375 T3 PL2209375 T3 PL 2209375T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- methods
- inhibitor compounds
- parp inhibitor
- parp
- Prior art date
Links
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97711507P | 2007-10-03 | 2007-10-03 | |
| EP08836018.5A EP2209375B1 (en) | 2007-10-03 | 2008-10-02 | Parp inhibitor compounds, compositions and methods of use |
| PCT/US2008/078606 WO2009046205A1 (en) | 2007-10-03 | 2008-10-02 | Parp inhibitor compounds, compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2209375T3 true PL2209375T3 (pl) | 2014-12-31 |
Family
ID=40526672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08836018T PL2209375T3 (pl) | 2007-10-03 | 2008-10-02 | Związki, kompozycje i metody stosowania inhibitorów PARP |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8236802B2 (pl) |
| EP (2) | EP2842956A1 (pl) |
| JP (1) | JP5439380B2 (pl) |
| KR (1) | KR101596526B1 (pl) |
| CN (1) | CN102083314B (pl) |
| AU (1) | AU2008308664B2 (pl) |
| BR (1) | BRPI0820518B1 (pl) |
| CA (1) | CA2700903C (pl) |
| CL (1) | CL2010000320A1 (pl) |
| CY (1) | CY1115747T1 (pl) |
| DK (1) | DK2209375T3 (pl) |
| ES (1) | ES2504690T3 (pl) |
| HR (1) | HRP20140853T1 (pl) |
| IL (1) | IL204776A (pl) |
| JO (1) | JO3170B1 (pl) |
| MX (1) | MX2010003564A (pl) |
| MY (1) | MY155237A (pl) |
| NZ (1) | NZ585012A (pl) |
| PL (1) | PL2209375T3 (pl) |
| PT (1) | PT2209375E (pl) |
| RU (1) | RU2485122C2 (pl) |
| SG (1) | SG185272A1 (pl) |
| SI (1) | SI2209375T1 (pl) |
| TW (1) | TWI426912B (pl) |
| UA (1) | UA99483C2 (pl) |
| WO (1) | WO2009046205A1 (pl) |
| ZA (1) | ZA201002317B (pl) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2319847A3 (en) | 2005-01-19 | 2012-06-20 | Eisai Inc. | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP |
| PL2209375T3 (pl) | 2007-10-03 | 2014-12-31 | Eisai Inc | Związki, kompozycje i metody stosowania inhibitorów PARP |
| EP2767537B1 (en) * | 2008-08-06 | 2017-04-12 | Medivation Technologies, Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| EP2322658A1 (en) | 2009-11-13 | 2011-05-18 | Centre National de la Recherche Scientifique (CNRS) | Signature for the diagnosis of breast cancer aggressiveness and genetic instability |
| DK2533640T3 (en) * | 2010-02-08 | 2017-01-23 | Medivation Technologies Inc | METHODS OF SYNTHESIS OF DIHYDROPYRIDOPHTHALAZINE DERIVATIVES |
| DK2582847T3 (en) | 2010-06-18 | 2016-12-19 | Myriad Genetics Inc | METHODS AND MATERIALS TO ASSESS loss of heterozygosity |
| WO2012074840A2 (en) * | 2010-11-22 | 2012-06-07 | The General Hospital Corporation | Compositions and methods for in vivo imaging |
| CA2865468C (en) * | 2011-03-11 | 2021-05-04 | Sarissa Inc. | Methods of treating cancer by inhibition of dna repair proteins |
| WO2012141990A1 (en) * | 2011-04-11 | 2012-10-18 | Abb Vie Inc. | Parp inhibitors for the treatment of cipn |
| CN103827314A (zh) | 2011-05-18 | 2014-05-28 | 国家科学研究中心 | 用于诊断癌侵袭性和遗传不稳定性的标记 |
| US9181266B2 (en) * | 2011-07-13 | 2015-11-10 | Novartis Ag | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| WO2013028495A1 (en) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
| EP2794907B2 (en) * | 2011-12-21 | 2022-11-23 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| CN104145030B (zh) | 2012-01-05 | 2016-10-12 | 国家科学研究中心 | 用于诊断肺癌侵袭性和遗传不稳定性的标记 |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| US10238630B2 (en) | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| WO2016138574A1 (en) | 2015-03-02 | 2016-09-09 | Sinai Health System | Homologous recombination factors |
| CN104945406B (zh) * | 2015-05-25 | 2017-10-10 | 苏州康润医药有限公司 | 氮杂非那烯‑3‑酮的衍生物、其制备方法及其作为parp抑制剂的应用 |
| ES2879434T3 (es) | 2015-07-23 | 2021-11-22 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| WO2018165615A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
| US12121518B2 (en) * | 2017-03-09 | 2024-10-22 | The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College | PARP-1 and methods of use thereof |
| IL322309A (en) | 2017-05-24 | 2025-09-01 | Novartis Ag | IL2 antibody grafted proteins and methods of use in cancer treatment |
| US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| MA54091A (fr) | 2018-10-30 | 2021-09-15 | Repare Therapeutics Inc | Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr |
| CN114502549B (zh) * | 2019-10-10 | 2024-10-25 | 埃斯特韦制药股份公司 | 针对疼痛具有多模态活性的高哌嗪基和高哌啶基喹唑啉-4(3h)-酮衍生物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021249996A1 (en) | 2020-06-08 | 2021-12-16 | Oncology Venture ApS | Compositions comprising 2x-121 and methods for treating coronavirus infection |
| CN114053276B (zh) * | 2020-07-30 | 2024-05-07 | 江苏天士力帝益药业有限公司 | 一种parp抑制剂tsl-1502中间体tsl-1502m的用途 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN121398822A (zh) | 2023-06-21 | 2026-01-23 | 四方生物科学有限公司 | 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
| US5032617A (en) | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
| US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| WO1999011622A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
| WO1999011644A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US5950784A (en) | 1997-09-03 | 1999-09-14 | Yang; Shu-Chiung C. | Hub structural improvement |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| AU9297998A (en) | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| WO1999059975A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| US6387902B1 (en) | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
| US6201020B1 (en) | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| HRP20010573B1 (en) | 1999-01-11 | 2006-04-30 | Agouron Pharmaceuticals | Tricyclic inhibitors of poly(adp-ribose) polymerases |
| ATE372337T1 (de) | 2000-02-01 | 2007-09-15 | Abbott Gmbh & Co Kg | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
| US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| BRPI0408284B8 (pt) * | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| ES2396334T3 (es) * | 2003-05-28 | 2013-02-20 | Eisai Inc. | Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP |
| CA2527832A1 (en) * | 2003-06-10 | 2004-12-23 | F. Hoffmann-La Roche Ag | 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives |
| ATE454893T1 (de) | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| WO2005053662A1 (en) | 2003-12-01 | 2005-06-16 | Kudos Pharmaceuticals Limited | Dna damage repair inhibitors for treatment of cancer |
| WO2006013060A1 (en) | 2004-08-04 | 2006-02-09 | Phosphonics Ltd | Substituted organopolysiloxanes and use thereof |
| EP2319847A3 (en) * | 2005-01-19 | 2012-06-20 | Eisai Inc. | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP |
| PL2209375T3 (pl) | 2007-10-03 | 2014-12-31 | Eisai Inc | Związki, kompozycje i metody stosowania inhibitorów PARP |
| WO2009137411A1 (en) | 2008-05-09 | 2009-11-12 | Allergan, Inc. | Therapeutic compounds |
| JP2013531007A (ja) | 2010-07-08 | 2013-08-01 | ワイス・エルエルシー | 皮膚障害の治療に有用な新規キノリンエステル |
-
2008
- 2008-10-02 PL PL08836018T patent/PL2209375T3/pl unknown
- 2008-10-02 CN CN200880118681.4A patent/CN102083314B/zh active Active
- 2008-10-02 RU RU2010117397/04A patent/RU2485122C2/ru active
- 2008-10-02 JP JP2010528132A patent/JP5439380B2/ja active Active
- 2008-10-02 NZ NZ585012A patent/NZ585012A/en not_active IP Right Cessation
- 2008-10-02 WO PCT/US2008/078606 patent/WO2009046205A1/en not_active Ceased
- 2008-10-02 EP EP14179976.7A patent/EP2842956A1/en not_active Withdrawn
- 2008-10-02 PT PT88360185T patent/PT2209375E/pt unknown
- 2008-10-02 ES ES08836018.5T patent/ES2504690T3/es active Active
- 2008-10-02 US US12/244,399 patent/US8236802B2/en active Active
- 2008-10-02 SI SI200831302T patent/SI2209375T1/sl unknown
- 2008-10-02 HR HRP20140853AT patent/HRP20140853T1/hr unknown
- 2008-10-02 AU AU2008308664A patent/AU2008308664B2/en active Active
- 2008-10-02 SG SG2012073482A patent/SG185272A1/en unknown
- 2008-10-02 CA CA2700903A patent/CA2700903C/en active Active
- 2008-10-02 DK DK08836018.5T patent/DK2209375T3/da active
- 2008-10-02 UA UAA201005117A patent/UA99483C2/ru unknown
- 2008-10-02 EP EP08836018.5A patent/EP2209375B1/en active Active
- 2008-10-02 KR KR1020107009588A patent/KR101596526B1/ko active Active
- 2008-10-02 MY MYPI2010001496A patent/MY155237A/en unknown
- 2008-10-02 MX MX2010003564A patent/MX2010003564A/es active IP Right Grant
- 2008-10-02 BR BRPI0820518-3A patent/BRPI0820518B1/pt active IP Right Grant
- 2008-10-03 TW TW097138166A patent/TWI426912B/zh active
- 2008-10-05 JO JOP/2008/0433A patent/JO3170B1/ar active
-
2010
- 2010-03-28 IL IL204776A patent/IL204776A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02317A patent/ZA201002317B/en unknown
- 2010-04-05 CL CL2010000320A patent/CL2010000320A1/es unknown
-
2012
- 2012-06-19 US US13/527,158 patent/US8894989B2/en active Active
-
2014
- 2014-09-25 CY CY20141100783T patent/CY1115747T1/el unknown
- 2014-11-11 US US14/538,447 patent/US20150141429A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201002317B (en) | Parp inhibitor compounds,compositions and methods of use | |
| HUS1900009I1 (hu) | Új vegyületek és készítmények, továbbá alkalmazási eljárásaik | |
| IL210462A0 (en) | Pyrimidine compounds, compositions and methods of use | |
| IL196956A0 (en) | Aza-benzofuranyl compounds and methods of use | |
| IL184303A0 (en) | Amino-pyridines as inhibitors of ??-secretase | |
| PT2397142T (pt) | Utilizações de inibidores da dpp iv | |
| IL205142A0 (en) | Pyridazinone derivatives as parp inhibitors | |
| ZA200909152B (en) | Triazolopyridine compounds and their use as ask inhibitors | |
| IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
| IL197869A0 (en) | Compositions of chk1 inhibitors | |
| ZA200802585B (en) | Pyridopyrimidinone inhibitors of Pl3Kα | |
| IL190292A0 (en) | PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka | |
| ZA201104463B (en) | Compounds and methods of use | |
| EP2211854A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS | |
| HRP20160902T1 (hr) | Pripravci i postupci uporabe forbolskih estera | |
| IL208483A0 (en) | Limk2 inhibitors, compositions comprising them, and methods of their use | |
| ZA200808017B (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| IL200387A0 (en) | Heterocylic compounds, compositions comprising them and methods of their use | |
| ZA201000992B (en) | Anti-viral compounds, compositions, and methods of use | |
| GB0621607D0 (en) | Inhibitors of c-Met | |
| IL205299A0 (en) | Parp inhibitor compounds | |
| ZA200900896B (en) | Aza-benzofuranyl compounds and methods of use | |
| ZA200901009B (en) | Aza-benzothiophenyl compounds and methods of use | |
| TH0801005083A (th) | สารประกอบ องค์ประกอบ และกรรมวิธีการใช้ตัวยับยั้ง parp | |
| GB0805693D0 (en) | Combinations of P13-delta and P13-gamma kinase inhibitor compounds |